OSE Immunotherapeutics Restructures Its Leadership with Two Key Appointments
OSE Immunotherapeutics announces the appointment of Thomas Gidoin as Deputy CEO and Aurore Morello as Chief Scientific Officer. These changes in its leadership team follow the confirmation of Marc Le Bozec as CEO on March 10.
Expanded Role for Thomas Gidoin
Thomas Gidoin, previously Chief Financial Officer, has been appointed Deputy CEO in addition to his current duties. In this expanded role, he will lead the company's financial strategy, develop investor relations, and oversee communications, as well as legal and corporate affairs. Gidoin, who joined OSE Immunotherapeutics in June 2025, has experience in corporate and financial strategy, capital markets, and corporate affairs, gained at private companies and those listed on Euronext Paris and the NASDAQ.
Aurore Morello Appointed as Chief Scientific Officer
Aurore Morello, PhD, previously Director of Research and R&D Program Director, has been appointed Chief Scientific Officer. She will oversee OSE's research strategy, drive R&D innovation, and lead the scientific teams in the development of monoclonal antibodies, immunocytokines, and RNA-based immunotherapies. She will also head OSE's Scientific Council. Dr. Morello, who holds a PhD in immunology and oncology from the University of Bordeaux and completed a postdoctoral fellowship at the Memorial Sloan Kettering Cancer Center in New York, joined OSE Immunotherapeutics in 2016.
